

PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

NCT04272658

Status	RECRUITING
Sponsor	University Hospital, Brest
Enrollment	56 participants

Plain Language Summary

This study uses a special type of full-body scan (PET/CT) to better understand how immunotherapy drugs are working in people with advanced skin cancer (melanoma). Researchers want to see whether a dynamic whole-body imaging approach can better track the cancer's response to treatment.

****You may be eligible if...****

- You are 18 or older
- You have been diagnosed with metastatic melanoma (melanoma that has spread)
- You are currently being treated with an immunotherapy drug such as Nivolumab, Pembrolizumab, or a combination of Ipilimumab and Nivolumab

****You may NOT be eligible if...****

- You are pregnant or breastfeeding
- You are under 18
- You have a different type of cancer
- You decline to participate

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (4)

- Patient older than 18 years
- With metastatic melanoma
- Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
- Having formulated a non-opposition

Exclusion (5)

- \- Minor patient < 18 years
- Pregnancy or breastfeeding
- Other type of tumor than metastatic melanoma
- Non-eligibility for the examination
- Refusal of participation

Locations (1 total)

Hospital University ff Brest, Brest, Finistere, France

<https://clinicaltrials.gov/study/NCT04272658>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.